Fermín
Sánchez-Guijo Martín
Catedrático de Universidad
Hospital Virgen de la Arrixaca
Murcia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Virgen de la Arrixaca (9)
2022
-
Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome
Frontiers in Immunology, Vol. 13
-
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270
2020
-
Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study
EClinicalMedicine, Vol. 25
-
Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)
Frontiers in Immunology
-
Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model
Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 12, pp. 2237-2244
-
Spanish Cell Therapy Network (TerCel): 15 years of successful collaborative translational research
Cytotherapy, Vol. 22, Núm. 1, pp. 1-5
2019
-
Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus
Frontiers in Immunology, Vol. 10, Núm. JUN
2018
-
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
Blood Cancer Journal, Vol. 8, Núm. 10